AI is transforming biotechnology faster than many expected. I’ve seen its impact in research labs, hospitals, and pharmaceutical companies, where machine learning models analyze genetic data, speed up drug discovery, and help doctors make life-saving decisions. The potential is enormous, but so are the ethical risks. AI decisions in biotechnology affect real people, from privacy concerns in genetic testing to the fairness of AI-driven treatments. If AI is to be trusted in this field, it must be developed and used responsibly. That means addressing questions of bias, accountability, transparency, and access. The challenge isn’t just about making AI smarter—it’s about making sure it serves people fairly and ethically.
Data Privacy and Security Must Come First
AI in biotechnology relies on vast amounts of sensitive data, including genetic records and personal health information. This data is valuable for research but also highly vulnerable to misuse. I’ve seen firsthand how breaches and unethical data sharing can shake public trust. Patients need to know exactly how their genetic data is being used and whether it’s properly protected.
One major issue is informed consent. Many people don’t realize that when they submit DNA samples for ancestry or health testing, their genetic information can be used for research, sold to third parties, or stored indefinitely. If AI is trained on data that wasn’t collected ethically, its results and recommendations are already compromised. Stricter regulations, encryption, and clear policies on data usage are the only way to ensure privacy and security in AI-driven biotechnology.
Bias in AI Can Lead to Unfair Treatment
AI is only as unbiased as the data it learns from. If an AI system is trained mostly on data from one demographic group, it won’t be accurate for others. I’ve seen cases where AI-driven diagnostics performed worse on patients from underrepresented backgrounds, simply because the system hadn’t been trained on diverse enough data. This isn’t just a technical problem—it’s an ethical failure.
In drug discovery, bias can mean that certain populations don’t receive treatments tailored to their needs. In medical AI, it can lead to incorrect diagnoses or recommendations. Addressing bias requires diverse datasets, continuous testing, and careful oversight. It’s not enough to assume that AI will be fair—we have to actively make it fair.
Transparency Matters: Understanding How AI Makes Decisions
One of the biggest challenges in AI-driven biotechnology is the “black box” problem. Many AI models produce results without providing an explanation for how they reached their conclusions. This creates serious ethical concerns, especially in healthcare. If an AI system recommends a treatment or diagnoses a disease, doctors and patients deserve to know why.
I’ve spoken with medical professionals who hesitate to trust AI-powered diagnostics because they don’t understand how the system arrived at its results. If AI is to be used in critical medical decisions, it needs to be explainable. This means developing models that provide clear reasoning and ensuring that AI doesn’t become an unquestioned authority. AI should assist human decision-making, not replace it.
Who is Accountable When AI Gets It Wrong?
AI is not perfect, and mistakes are inevitable. The question is, who is responsible when AI in biotechnology makes an error? If an AI misdiagnoses a patient, causing them to receive the wrong treatment, is the responsibility on the hospital, the software developer, or the regulatory body that approved the AI?
Accountability in AI-driven biotechnology is still a legal gray area. Without clear guidelines, patients could suffer from AI-related errors with no real recourse. Establishing responsibility is crucial for ethical AI use. Developers must test their systems rigorously, healthcare providers must ensure proper oversight, and regulators must put clear policies in place. Trust in AI depends on knowing that someone is accountable when things go wrong.
AI in Biotechnology Shouldn’t Widen Healthcare Inequality
AI has the potential to make healthcare more efficient and accessible, but without careful implementation, it could also deepen existing inequalities. Advanced AI-driven treatments and diagnostics often come with high costs, meaning only the wealthiest patients or institutions can afford them.
If AI-powered biotechnology is to benefit everyone, accessibility must be prioritized. This means developing affordable AI-driven medical tools, ensuring public healthcare systems can integrate AI advancements, and preventing life-saving technologies from becoming a luxury. Ethical AI isn’t just about preventing harm—it’s about ensuring equal benefits for all.
Dual-Use Technology: AI for Good or for Harm?
One of the most overlooked ethical issues in AI-driven biotechnology is the risk of dual-use technology. Many AI applications are developed for positive purposes—such as improving drug discovery or advancing genetic research—but the same technologies can be misused. AI models designed to edit genes could be repurposed for unethical human modifications. AI-driven drug design could be exploited to develop harmful biological agents.
The reality is that every powerful technology carries risks, and AI is no exception. Researchers and policymakers must establish strict guidelines to prevent misuse. Ethical responsibility means anticipating potential threats and putting safeguards in place before AI is misapplied.
Key Ethical Concerns in AI-Driven Biotechnology
- Data privacy – Protecting genetic and medical information from misuse.
- Bias in AI models – Ensuring fair and accurate medical decisions for all.
- Transparency – Making AI decision-making processes understandable.
- Accountability – Defining responsibility when AI systems make errors.
- Accessibility – Preventing AI-powered healthcare from benefiting only the wealthy.
- Dual-use risks – Safeguarding AI biotechnology from unethical applications.
In Conclusion
AI is already reshaping biotechnology, and its impact will only grow. The ethical challenges surrounding AI in this field are not just theoretical—they affect real people’s lives. Issues of privacy, bias, transparency, accountability, and accessibility must be addressed to ensure AI serves humanity responsibly. The goal is not to slow technological progress but to guide it in a way that benefits everyone. AI in biotechnology must be developed with a commitment to fairness, security, and ethical responsibility. If these challenges are handled properly, AI can revolutionize medicine without compromising the fundamental values that protect individuals and society.
“Want to explore more discussions on technology and ethics? Check out my podcast, where I dive deeper into these critical topics: Listen here Spotify.”
Nirdosh Jagota is Managing Partner at GRQ Biotech Advisors with 30+ years in the biotech industry. A former executive at Amgen, Genentech/Roche, Merck, and Pfizer, he has led >25 NDAs/BLAs/MAAs and hundreds of INDs across global regulatory, quality, and compliance.